Are Peptides Being Overhyped?

Peptides are a hot topic in health circles right now. They claim to relieve us of a multitude of complaints, from anti-aging and weight loss to performance. But are they living up to the hype? Some peptide-based medications have been rigorously studied and FDA-approved. Many others are marketed based on limited evidence, early research, or bold claims that go beyond what science currently supports.

​
There is absolutely no question that peptides are, categorically, heavily overhyped these days.

Peptides aren’t inherently problematic or ineffective. Where we run into issues is that we are overgeneralizing. The word peptide describes a type of molecule, and not all of them do the same thing. Rather than evaluating each specific peptide according to its own benefits and risks, it’s hard for people to hear through the overgeneralizing and marketing hype.

​It would be like lumping Aleve, aspirin, and Advil together simply because they are all NSAIDs without considering the differences among them. In fact, peptides are an even broader category than NSAIDs. Just as Aspirin and Ibuprofen are chemically distinct drugs within the NSAID class with different profiles, “peptide” refers to a structural classification of molecules, not a single therapeutic effect.

​To illustrate the difference, GLP-1 is a naturally occurring peptide hormone produced by the body. Semaglutide, best known by the brand names Ozempic and Wegovy, is a modified peptide analog that activates the GLP-1 receptor. Tirzepatide (Mounjaro and Zepbound) is also a peptide-based medication, but it activates both GIP and GLP-1 receptors.

​These medications did not become widely used and touted only because they are peptides. They were evaluated in large, randomized clinical trials, went through the FDA’s formal approval process, and continue to be studied for adverse events even after approval and widespread use.
​

The problem arises when peptides promoted by biohackers, wellness clinics, and longevity advocates are treated as though early lab or animal findings prove safety and effectiveness. Interesting preliminary research may make a peptide a worthwhile subject for further study, but it does not automatically make it an established treatment.
​

We can’t just say that because a peptide affects a particular pathway, it must be beneficial. We also can’t assume that changing a pathway is without risk. The dose, administration, manufacturing quality, and effects in the body all matter.
​

BPC-157 is a good example of how the peptide market may be overstating potential benefits. It is often marketed for gastrointestinal health, injury recovery, tissue healing, and inflammation. However, FDA reviewers did not find enough evidence of effectiveness to consider it safe. They also brought up concerns about impurities, aggregation, and immune system reactions. There has been limited human exposure, but the evidence is nowhere near the level of that supporting approved GLP-1 medications.

​Just recently, an FDA advisory committee recommended that six peptides be considered for inclusion on the list of substances that certain pharmacies may use in compounding. That recommendation is nonbinding. It is not FDA-approved, and it does not mean the products have been established as safe and effective. In other words, the FDA committee discussed and recommended that certain peptides may be allowed for use by compounding pharmacies, but that recommendation does not mean the FDA has approved those peptides as medications.

​This raises another important concern: where is the product coming from? A product prepared by a licensed compounding pharmacy is overseen, but still doesn’t have the same level of scrutiny as an approved pharmaceutical drug.

​The challenge with emerging therapies is that excitement often moves faster than evidence – especially when it hits social media. Many medical breakthroughs begin with promising discoveries, but the path from a biological mechanism to a safe and effective treatment requires years of careful research. Peptides may hold significant potential, but potential alone is not the same as proof.

Before considering any peptide therapy, it is important to ask the same questions we would ask of any medical treatment: What condition is it intended to treat? Has it been studied in humans? Are the benefits supported by clinical trials? Are the risks understood? And is the product manufactured with appropriate quality standards?

Peptide science is legitimate, but individual compounds need to be evaluated in the same way that GLP-1 medications are, so we aren’t jumping into the unknown.